John Entwistle, III, MD, PhD

Contact Dr. Entwistle

1025 Walnut Street
College Building, Suite 607E
Philadelphia, PA 19107

(215) 955-6996
(215) 955-6010 fax

Most Recent Peer-reviewed Publications

  1. The American Association for Thoracic Surgery 2016 Ethics Forum: Cost-effectiveness and the ethics of left ventricular assist device therapy
  2. Quality of life and mid-term survival of patients bridged with extracorporeal membrane oxygenation to left ventricular assist device
  3. PREVENtion of HeartMate II Pump Thrombosis Through Clinical Management: The PREVENT multi-center study
  4. Should Family Presence Be Allowed During Cardiopulmonary Resuscitation?
  5. The Impact of Vascular Complications on Survival of Patients on Venoarterial Extracorporeal Membrane Oxygenation
  6. Massive thrombosis of the transplanted heart in the early postoperative period
  7. Left ventricular assist device driveline infection and the frequency of dressing change in hospitalized patients
  8. Veno-venous extracorporeal membrane oxygenation using a double-lumen bi-caval cannula for severe respiratory failure post total artificial heart implantation
  9. Late Failure of Amplatzer Device Closure of a Patent Foramen Ovale
  10. Two-vessel off-pump coronary artery bypass grafting by left thoracotomy in a complex reoperative case
  11. The ethics of mechanical support: The need for new guidelines
  12. Ethical considerations for ventricular assist device support: A 10-point model
  13. Carbon monoxide releasing molecule-2 improves coagulation in patient plasma in vitro following cardiopulmonary bypass
  14. Primary synovial sarcoma of the lung with intra-cardiac extension
  15. Comparison of eight prosthetic aortic valves in a cadaver model
  16. Superior vena cava rupture during balloon angioplasty and stent placement to relieve superior vena cava syndrome: a case report.
  17. Swan-Ganz monitoring of the AbioCor artificial heart
  18. Postoperative nesiritide use following high-risk mitral valve replacement.
  19. Use of the AbioCor replacement heart as destination therapy for end-stage heart failure with irreversible pulmonary hypertension
  20. Postoperative nesiritide use following high-risk mitral valve replacement